Search for predictors of immune checkpoint inhibitors in patients with malignant pleural mesothelioma

akamura Yoichi0 个研究点目标入组 20 人开始时间: 2021年4月14日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1 Patients with unresectable advanced/recurrent malignant pleural mesothelioma who have indication for treatment with immune checkpoint inhibitors and have measurable lesions by modified Response Evaluation Criteria in Solid Tumors (mRECIST).
•2 Patients who are 20 years of age or older at the time of obtaining informed consent.
•3 Patients who have received sufficient explanation before participating in this study, and who have obtained sufficient understanding and voluntary written informed consent of the patient. Patients who lack the ability to consent are not included.

•1 Hepatitis B virus: HBs antigen or hepatitis C virus: HCV-RNA positive patients.
•2 Patients with a positive human immunodeficiency virus (HIV) test.
•3 Patients judged by the principal investigator or coordinator to be inappropriate as research subjects.
•4 Patients who have received other immune checkpoint inhibitors, previously.

发起方

akamura Yoichi